Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world bevacizumab in advanced RAS-mutated colorectal cancer
ChiCTR2100042553Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in colorectal adenocarcinoma, sponsored by Anhui Provincial Tumor Hospital. Primary endpoints: Progression-Free Survival and Overall Survival. Started Feb 2021; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100042553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042553.